-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Observations from a fund not headquartered in your feed
It’s widely known that more than 90% of start-ups fail. The most common reasons that tech start-ups fail at the post-seed / series A stage relate to inability to validate…
In his book ‘Capitalism, Socialism, and Democracy’, Joseph Schumpeter argues that capitalism is ever-changing as new innovations create new markets and rendering existing ones obsolete over time, thus ‘destructing’ them…
Valuation / ownership is one of the key subjects for negotiation between VCs and start-ups, especially at the seed stage where technology validation, go-to-market and commercial risks are high. The…
VC investment in deep tech is on the rise. But how is deep tech defined? My favorite definition of deep tech is provided by Nathan Benaich (Founder and General Partner…
All my previous posts have been related to the market and financial aspects of the pharma and biotech industry. In this post, I am focusing on the human resources aspects…
Few years back, I wrote a post where I constructed the efficient frontier curve based on a combination of 2 assets: biotech stocks (large cap and mid cap) and US…
How do VCs estimate their return on investment? There have been various studies which have produced varying results due to the different nature of VCs in terms of location, industry…
Over recent years, biotechnology has uncovered new horizons in transforming patients’ lives. Insulin was the first biologic drug and was approved in 1982. Currently, the biotech market is valued at…
Celgene recently disposed Otezla indicated for the treatment of psoriasis and psoriatic arthritis to Amgen in $13.4bn deal. Therefore, the question that is raised at this point is whether the…
The methodology for valuing biotech products using the risk-adjusted NPV (‘rNPV’) approach has been well established. The concept behind the rNPV method is taking into account the risk of success…
Big pharma companies have undoubtedly been suffering from low R&D productivity pushing them to revise their business strategy. Although inorganic R&D strategies through M&A and in-licensing deals have boosted big…
Regulators and payers have raised major concerns over recent spikes in drug prices. Unjustified high drug prices (see Valeant case) have triggered not only political comments from U.S. presidential candidates in…
DSD 